Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fallopian Tube Cancer - Overview
Fallopian Tube Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fallopian Tube Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fallopian Tube Cancer - Companies Involved in Therapeutics Development
Fallopian Tube Cancer - Drug Profiles
Fallopian Tube Cancer - Dormant Projects
Fallopian Tube Cancer - Discontinued Products
Fallopian Tube Cancer - Product Development Milestones
Featured News & Press Releases
Jul 22, 2022: EMA recommends restricting use of cancer medicine Rubraca
Jul 05, 2022: EMA recommends granting a marketing authorisation for biosimilar Bevacizumab
May 31, 2022: Greenfire Bio to update progress on phase 1 clinical trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022
May 19, 2022: EMA starts review of rucaparib
Feb 24, 2022: Once-a-day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS
Dec 10, 2021: Inceptua receives formal approval of the transfer of Oasmia’s marketing authorization for Apealea
Dec 02, 2021: BeiGene announces inclusion in the Chi tiol Reimbursement Drug List (NRDL) first listing for Pamiparib
Feb 25, 2021: Viatris receives positive CHMP opinion for Abevmy for use as treatment of various cancers
Dec 28, 2020: Zai Lab announces inclusion of ZEJULA (Niraparib) in Chi’s tiol Reimbursement Drug List
Oct 05, 2020: Elevar Therapeutics and Taiba Middle East FZ partner to commercialize Apealea (paclitaxel micellar) in the Middle East and North Africa region
Jul 27, 2020: Elevar Therapeutics and Tanner Pharma Group announce global med patient program to provide access to Apealea (paclitaxel micellar)
Jun 22, 2020: Preclinical data for PRGN-3005 UltraCAR-T demonstrate superior expansion and persistence of UltraCAR-T compared to traditiol CAR-T
Apr 30, 2020: GSK gets FDA approval for expanded use of ovarian cancer drug Zejula
Apr 20, 2020: Sutro Biopharma to host conference call, to provide clinical update on its STRO-002 Antibody-Drug Conjugate
Mar 16, 2020: Zai Lab announces acceptance of sNDA submission of ZEJULA (Niraparib) for first-line maintence treatment of ovarian cancer in Chi by the NMPA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Fallopian Tube Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Fallopian Tube Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fallopian Tube Cancer - Dormant Projects, 2022
Fallopian Tube Cancer - Discontinued Products, 2022
Fallopian Tube Cancer - Discontinued Products, 2022 (Contd..1)